Vivozon Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Vivozon Pharmaceutical has been growing earnings at an average annual rate of 17.8%, while the Semiconductor industry saw earnings growing at 8.6% annually. Revenues have been growing at an average rate of 13.2% per year.
Key information
17.8%
Earnings growth rate
26.1%
EPS growth rate
Semiconductor Industry Growth | 23.5% |
Revenue growth rate | 13.2% |
Return on equity | -2.8% |
Net Margin | -3.4% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 40% But Its Business Is Yet to Catch Up
Dec 12We Think Vivozon Pharmaceutical (KOSDAQ:082800) Is Taking Some Risk With Its Debt
Dec 02Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) Shares Climb 35% But Its Business Is Yet to Catch Up
Oct 28What Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) 33% Share Price Gain Is Not Telling You
Aug 02Vivozon Pharmaceutical (KOSDAQ:082800) Has A Somewhat Strained Balance Sheet
Jul 29Some Shareholders Feeling Restless Over Vivozon Pharmaceutical Co., Ltd.'s (KOSDAQ:082800) P/S Ratio
Jun 04We Think Vivozon Pharmaceutical (KOSDAQ:082800) Has A Fair Chunk Of Debt
Mar 23Is Vivozon Healthcare (KOSDAQ:082800) A Risky Investment?
May 06Estimating The Intrinsic Value Of Vivozon Healthcare, Inc. (KOSDAQ:082800)
Feb 18Did You Miss Vivozon Healthcare's (KOSDAQ:082800) Impressive 116% Share Price Gain?
Dec 04Revenue & Expenses Breakdown
How Vivozon Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 87,275 | -2,940 | 34,412 | 3,524 |
30 Jun 24 | 81,518 | -2,725 | 29,784 | 3,206 |
31 Mar 24 | 77,515 | -1,988 | 25,526 | 2,999 |
31 Dec 23 | 71,318 | -2,214 | 22,693 | 2,541 |
30 Sep 23 | 63,558 | -15,016 | 26,500 | 2,734 |
30 Jun 23 | 59,402 | -16,984 | 26,755 | 2,616 |
31 Mar 23 | 51,411 | -20,947 | 27,085 | 2,322 |
31 Dec 22 | 51,564 | -26,079 | 27,744 | 1,927 |
30 Sep 22 | 52,429 | -65,746 | 27,027 | 1,777 |
30 Jun 22 | 52,846 | -72,472 | 29,089 | 1,781 |
31 Mar 22 | 57,175 | -69,523 | 31,096 | 3,834 |
31 Dec 21 | 57,560 | -69,457 | 31,682 | 3,935 |
30 Sep 21 | 56,999 | -47,728 | 28,047 | 5,721 |
30 Jun 21 | 51,123 | -41,492 | 21,586 | 5,388 |
31 Mar 21 | 48,923 | -39,366 | 16,386 | 3,092 |
31 Dec 20 | 43,592 | -43,754 | 10,808 | 2,870 |
30 Sep 20 | 40,671 | -30,829 | 4,525 | 363 |
31 Dec 19 | 44,953 | -21,631 | 4,931 | 380 |
30 Sep 19 | 44,701 | -975 | 8,340 | 400 |
30 Jun 19 | 43,254 | -9,392 | 8,583 | 402 |
31 Mar 19 | 45,740 | -8,313 | 7,306 | 368 |
31 Dec 18 | 46,003 | -8,534 | 7,252 | 360 |
Quality Earnings: A082800 is currently unprofitable.
Growing Profit Margin: A082800 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A082800 is unprofitable, but has reduced losses over the past 5 years at a rate of 17.8% per year.
Accelerating Growth: Unable to compare A082800's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A082800 is unprofitable, making it difficult to compare its past year earnings growth to the Semiconductor industry (7.4%).
Return on Equity
High ROE: A082800 has a negative Return on Equity (-2.8%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/01 01:18 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivozon Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mok Hyun Ji | MERITZ Securities Co., Ltd. |
Hyun Yong Kim | SK Securities Co., Ltd. |